Back to Research Home
BIIBBiogen Inc
Health Care · Biotechnology · Large
$250.69−1.24%
As of 23 Oct 2026Mkt cap $32.9B
Stage 13
AVOID
Fundamentals
39.6/75
Technical
4.8/15
Independent
44.4/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- +10.7%
- 3M
- +25.3%
- 6M
- +36.0%
- 1Y
- +69.7%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 44.4xHist median 15.0x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- 12.7%
- Operating margin
- 30.8%
- FCF margin
- 20.7%
- Current ratio
- 2.7x
Growth
- Revenue growth
- +2.2%Latest FY YoY
- Revenue CAGR
- −2.6%
- EPS CAGR
- −4.1%
- FCF CAGR
- −11.8%
Capital
- Share-count trend
- +0.5%3Y annualised
- Net debt
- $3.6B1.6x OCF
Annual trend
- CAGR 2021–2025
- −2.6%
- Latest · 2025
- $10B
- YoY
- +2.2%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-28
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded